A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

David R. Boulware , Matthew F Pullen , Ananta Bangdiwala , David R. Boulware , Matthew F Pullen , Ananta Bangdiwala , Katelyn A Pastick , Sarah M Lofgren , Elizabeth C Okafor , Caleb P Skipper , Alanna A Nascene , Melanie R. Nicol , Mahsa Abassi , Nicole Engen , Matthew P. Cheng , Derek LaBar , Sylvain Lother , Lauren J MacKenzie , Glen Drobot , Nicole Marten , Ryan Zarychanski , Lauren E. Kelly , Ilan S. Schwartz , Emily G. McDonald , Radha Rajasingham , Todd C. Lee , Kathy Huppler Hullsiek
2020 New England Journal of Medicine 1,395 citations

Abstract

After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668.).

Keywords

HydroxychloroquineMedicinePlaceboAsymptomaticFace shieldPre-exposure prophylaxisRandomized controlled trialCoronavirus disease 2019 (COVID-19)Confidence intervalIncidence (geometry)Internal medicineDiseaseVirologyPathologyHealth careHuman immunodeficiency virus (HIV)Men who have sex with men

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
383
Issue
6
Pages
517-525
Citations
1395
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1395
OpenAlex

Cite This

David R. Boulware, Matthew F Pullen, Ananta Bangdiwala et al. (2020). A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine , 383 (6) , 517-525. https://doi.org/10.1056/nejmoa2016638

Identifiers

DOI
10.1056/nejmoa2016638